QIBA Process Committee Call

Wednesday, December 13, 2017 at 3 PM CT Call Summary

Attendees:

Kevin O'Donnell, MASc (Co-Chair)

Brian Garra, MD

RSNA Staff:

Edward Jackson, PhD

Eric Perlman, MD

Nicholas Petrick, PhD

Susan Weinmann

Site Level Assessment and Guidance

- Site level assessment is the basis for Profile Stage 4: Claim Confirmed and Stage 5: Clinically Confirmed
- More information on Profile Stages can be found on the QIBA Wiki at: http://qibawiki.rsna.org/index.php/QIBA Profile Stages
- Discussion ensued regarding the use of algorithms to assess repeatability as an alternative to testretest, as suggested on the 2017 Q4 CT Coordinating Cmte call
 - The importance of composite evaluation at a site and having a method/system to check a site's conformance capability was noted
 - It was cautioned that biomarkers with a significant amount of variability may prove difficult to assess conformance
- Suggestion to offer a t-con training "boot camp," on assessment and conformance procedures
 - o At least one representative from each QIBA BC to participate
 - Topics to include: how Claims are formed, Profile structure, movement through Profile stages
 - Decision made to assign a Process liaison for each BC in efforts to enhance lines of communication regarding processes with all BCs
- List of designated seats/roles on each BC to be composed so that when a new BC is formed, responsibilities will be clearly defined and covered

Assessment Procedure Guidance

- In preparation for this call, Dr. Obuchowski reviewed and addressed the comments in this document
- Title of this document to be updated to: "Guidance for Profile Authors Drafting Statistical Assumption and Composite Performance Assessment Procedures"
- Ultrasound example (deliberately targeting ground truth using a phantom) of properties of a dataset to be added
- Dr. Obuchowski added detail to Section 3; what constitutes a "retest" to be defined
- Mr. O'Donnell to make edits and post to the QIBA Wiki at:
 http://qibawiki.rsna.org/index.php/Assessment Procedure Guidance and contact those who have tasks due prior to the end of the year

Other Business

- Process Committee call will be moving to Tuesdays at 3 PM CT, effective January 9, 2018; Dr. Garra's attendance in question until March 2018 due to his transition from the VA hospital to part-time at FDA and in private practice
- This new time slot will allow Dr. Karam to join calls more frequently

Next Call: Tuesday, January 9, 2018 at 3 PM CT New day!